We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · August 23, 2021

Abemaciclib + Fulvestrant as First-and Second-Line Therapy for HR+, HER2− Advanced Breast Cancer

Clinical Cancer Research


Additional Info

Clinical Cancer Research
MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR+, HER2- Advanced Breast Cancer
Clin. Cancer Res 2021 Aug 10;[EPub Ahead of Print], P Neven, SRD Johnston, M Toi, J Sohn, K Inoue, X Pivot, O Burdaeva, M Okera, N Masuda, PA Kaufman, H Koh, EM Grischke, P Conte, Y Lu, N Haddad, KC Hurt, A Llombart-Cussac, GW Sledge

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading